Skip to main content
Year archive

Ascletis Pharma Inc. — 2020 filings

All 98 regulatory filings released by Ascletis Pharma Inc. (1672) in 2020, sourced directly from the official regulator.

98 Filings
2020 Period
2020 filings (98)
Filing Released Lang
GRANT OF SHARE OPTIONS
Regulatory Filings
2020-12-31 English
VOLUNTARY ANNOUNCEMENT - FIRST SUBJECT DOSED WITH GANNEX'S FXR AGONIST ASC42 IN A U.S. PHASE I TRIAL
Regulatory Filings
2020-12-28 English
GRANT OF SHARE OPTIONS
Regulatory Filings
2020-12-22 English
VOLUNTARY ANNOUNCEMENT - OVERWEIGHT AND OBESE SUBJECTS DOSED WITH ASC41 TABLETS IN A PHASE Ib TRIAL
Regulatory Filings
2020-12-22 English
Next Day Disclosure Return
Regulatory Filings
2020-12-14 English
VOLUNTARY ANNOUNCEMENT - GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42, AN FXR AGONIST
Regulatory Filings
2020-12-14 English
Next Day Disclosure Return
Regulatory Filings
2020-12-04 English
VOLUNTARY ANNOUNCEMENT - ASC22 (ENVAFOLIMAB) IS SAFE AND WELL TOLERATED IN PHASE IIa HBV STUDY AND PHASE IIb HBV CLINICAL TRIAL HAS BEEN INITIATED
Regulatory Filings
2020-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Regulatory Filings
2020-12-02 English
Next Day Disclosure Return
Regulatory Filings
2020-12-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 November 2020
Regulatory Filings
2020-12-01 English
Next Day Disclosure Return
Regulatory Filings
2020-11-30 English
Next Day Disclosure Return
Regulatory Filings
2020-11-23 English
Next Day Disclosure Return
Regulatory Filings
2020-11-19 English
VOLUNTARY ANNOUNCEMENT - ASC40 (TVB-2640) PHASE II NASH TRIAL COMPLETED PATIENT ENROLLMENT IN CHINA
Regulatory Filings
2020-11-19 English
CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING
Regulatory Filings
2020-11-18 English
Land Parcel No. G11207-1, Pingshan New Area, Longgang, Shenzhen City Urban Renewal Project Further Announcement on Developers' Right and Interest Restructuring
Regulatory Filings
2020-11-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
Regulatory Filings
2020-11-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2020
Regulatory Filings
2020-11-02 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNOUNCEMENT OF INTERIM RESULTS 2020
Regulatory Filings
2020-10-30 English
Next Day Disclosure Return
Regulatory Filings
2020-10-27 English
Next Day Disclosure Return
Regulatory Filings
2020-10-21 English
Next Day Disclosure Return
Regulatory Filings
2020-10-19 English
Next Day Disclosure Return
Regulatory Filings
2020-10-16 English
Next Day Disclosure Return
Regulatory Filings
2020-10-15 English
Next Day Disclosure Return
Regulatory Filings
2020-10-14 English
Next Day Disclosure Return
Regulatory Filings
2020-10-12 English
VOLUNTARY ANNOUNCEMENT - GANNEX RECEIVED U.S. IND APPROVAL FOR ITS NASH DRUG CANDIDATE ASC42, AN FXR AGONIST
Regulatory Filings
2020-10-12 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 September 2020
Regulatory Filings
2020-10-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
Regulatory Filings
2020-09-30 English
Interim Report 2020
Regulatory Filings
2020-09-24 English
INTERIM REPORT 2020
Regulatory Filings
2020-09-17 English
VOLUNTARY ANNOUNCEMENT - GANNEX FILED IND IN THE U.S. FOR ITS NASH DRUG CANDIDATE ASC42, AN FXR AGONIST
Regulatory Filings
2020-09-14 English
VOLUNTARY ANNOUNCEMENT - GANNEX AND GALMED EXPAND DEVELOPMENT PROGRAMS FOR NASH THROUGH RESEARCH COLLABORATION OF ARAMCHOL AND ASC41 (THR-BETA AGONIST)
Regulatory Filings
2020-09-09 English
VOLUNTARY ANNOUNCEMENT - PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
Regulatory Filings
2020-09-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
Regulatory Filings
2020-09-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2020
Regulatory Filings
2020-09-01 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020
Regulatory Filings
2020-08-28 English
ANNOUNCEMENT OF INTERIM RESULTS 2020
Regulatory Filings
2020-08-25 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF BRIDGING STUDY OF ASC18
Regulatory Filings
2020-08-20 English
VOLUNTARY ANNOUNCEMENT - FIRST HBV PATIENT DOSED IN PHASE IIa CLINICAL TRIAL OF ASC22, A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY
Regulatory Filings
2020-08-17 English
DATE OF BOARD MEETING
Regulatory Filings
2020-08-13 English
NOTICE OF BOARD MEETING
Regulatory Filings
2020-08-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
Regulatory Filings
2020-08-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2020
Regulatory Filings
2020-08-04 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING ALL-ORAL HCV TREATMENT
Regulatory Filings
2020-07-31 English
VOLUNTARY ANNOUNCEMENT - BRIDGING STUDY IN CHINA COMPLETED FOR NASH DRUG CANDIDATE ASC40
Regulatory Filings
2020-07-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
Regulatory Filings
2020-07-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 June 2020
Regulatory Filings
2020-07-02 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Regulatory Filings
2020-06-30 English
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; CHANGE IN COMPOSITION OF THE BOARD COMMITTEES
Regulatory Filings
2020-06-30 English
VOLUNTARY ANNOUNCEMENT - ASC40 (TVB2640) SIGNIFICANTLY REDUCED LIVER FAT WITH A 61% RESPONDER RATE IN PHASE 2 NASH TRIAL
Regulatory Filings
2020-06-17 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 15, 2020
Regulatory Filings
2020-06-15 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 12 JUNE 2020
Regulatory Filings
2020-06-12 English
Land Parcel No. G11207-1, Pingshan New Area, Longgang, Shenzhen City Urban Renewal Project Developers' Right and Interest Restructuring
Regulatory Filings
2020-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
Regulatory Filings
2020-06-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 May 2020
Regulatory Filings
2020-06-01 English
CLARIFICATION ANNOUNCEMENT - FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING
Regulatory Filings
2020-05-28 English
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2020-05-13 English
GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2020-05-13 English
Annual Report 2019
Regulatory Filings
2020-05-13 English
FORM OF PROXY FOR ANNUAL GENERAL MEETING (or any adjournment thereof)
Regulatory Filings
2020-05-13 English
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIALS OF NON-ALCOHOLIC STEATOHEPATITIS DRUG ASC41, A THR-BETA AGONIST
Regulatory Filings
2020-05-13 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
Regulatory Filings
2020-05-13 English
Form of Proxy for the 2020 Annual General Meeting
Regulatory Filings
2020-05-13 English
Notice of 2020 Annual General Meeting
Regulatory Filings
2020-05-13 English
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-election of Retiring Directors and Notice of Annual General Meeting
Regulatory Filings
2020-05-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
Regulatory Filings
2020-05-06 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 April 2020
Regulatory Filings
2020-05-04 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Annual Report 2019
Regulatory Filings
2020-04-22 English
Annual Report 2019
Regulatory Filings
2020-04-22 English
ANNOUNCEMENT ON UPDATE OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019
Regulatory Filings
2020-04-17 English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL OF ASC09/RITONAVIR FIXED-DOSE COMBINATION
Regulatory Filings
2020-04-13 English
DATE OF BOARD MEETING
Regulatory Filings
2020-04-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
Regulatory Filings
2020-04-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 March 2020
Regulatory Filings
2020-04-01 English
VOLUNTARY ANNOUNCEMENT - DATA ON NASH CANDIDATE ASC40 TO BE PRESENTED AT EASL ILC 2020
Regulatory Filings
2020-04-01 English
GRANT OF SHARE OPTIONS
Regulatory Filings
2020-03-31 English
UNAUDITED RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019
Regulatory Filings
2020-03-25 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2019
Regulatory Filings
2020-03-24 English
DATE OF BOARD MEETING
Regulatory Filings
2020-03-12 English
NOTICE OF BOARD MEETING
Regulatory Filings
2020-03-11 English
ANNOUNCEMENT - INSIDE INFORMATION - PROGRESS OF THE SMALL SAMPLE CLINICAL TRIAL OF GANOVO (DANOPREVIR) AND RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA
Regulatory Filings
2020-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
Regulatory Filings
2020-03-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 29 February 2020
Regulatory Filings
2020-03-02 English
ANNOUNCEMENT - INSIDE INFORMATION - CLINICAL TRIAL OF GANOVO AND RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA
Regulatory Filings
2020-02-27 English
APPLICATION FOR CATEGORY I DRUG ASC41 FOR CLINICAL TRIALS OF NONALCOHOLIC STEATOHEPATITIS (NASH) INDICATION ACCEPTED
Regulatory Filings
2020-02-18 English
INSIDE INFORMATION - RITONAVIR OBTAINED APPROVAL FROM RELEVANT REGULATORY AUTHORITIES OF ZHEJIANG PROVINCE TO CONDUCT STUDY ON THE TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA
Regulatory Filings
2020-02-17 English
ANNOUNCEMENT - INSIDE INFORMATION - ASC09/RITONAVIR COMBINED WITH INTERFERON ALPHA ATOMIZATION OBTAINED APPROVAL FROM THE SECOND AFFILIATED HOSPITAL ETHICS COMMITTEE OF CHONGQING MEDICAL UNIVERSI
Regulatory Filings
2020-02-13 English
ANNOUNCEMENT - INSIDE INFORMATION - ASC09/RITONAVIR CLINICAL TRIAL FOR NEW CORONAVIRUS INFECTION INITIATED ACROSS ZHEJIANG PROVINCE AFTER WUHAN
Regulatory Filings
2020-02-07 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 January 2020
Regulatory Filings
2020-02-06 English
ANNOUNCEMENT - INSIDE INFORMATION - ASC09 FIXED-DOSE COMBINATION AND RITONAVIR OBTAINED APPROVAL FROM WUHAN TONGJI HOSPITAL ETHICS COMMITTEE TO CONDUCT CLINICAL TRIAL ON THE TREATMENT OF NEW CORONAVIR
Regulatory Filings
2020-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
Regulatory Filings
2020-02-03 English
ANNOUNCEMENT - INSIDE INFORMATION - PROGRESS REGARDING ASC09 FIXED-DOSE COMBINATION AND RITONAVIR IN TERMS OF THE TREATMENT OF NEW CORONAVIRUS INFECTIONS
Regulatory Filings
2020-02-03 English
CLARIFICATION ANNOUNCEMENT
Regulatory Filings
2020-01-29 English
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIALS OF HBV IN CHINA FOR ASC22, A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY
Regulatory Filings
2020-01-23 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2019
Regulatory Filings
2020-01-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
Regulatory Filings
2020-01-02 English